Global Finance News
19 Mar 2026, 19:39
Blackstone Credit & Insurance announced that it is leading a $1.3 billion financing to support the merger of Paratek Pharmaceuticals and Radius Health.
The transaction will create a larger specialty pharmaceutical company with a diversified portfolio of innovative medicines, targeting long-term growth in key therapeutic areas. The combined platform is expected to generate nearly $1 billion in annual revenue in 2026.
Backed by B-FLEXION Life Sciences, the merger brings together complementary businesses to strengthen Paratek’s strategy of building a scalable pharmaceutical platform. Blackstone highlighted the deal as an example of its ability to provide large-scale capital solutions to support growth in the life sciences sector.
The transaction will create a larger specialty pharmaceutical company with a diversified portfolio of innovative medicines, targeting long-term growth in key therapeutic areas. The combined platform is expected to generate nearly $1 billion in annual revenue in 2026.
Backed by B-FLEXION Life Sciences, the merger brings together complementary businesses to strengthen Paratek’s strategy of building a scalable pharmaceutical platform. Blackstone highlighted the deal as an example of its ability to provide large-scale capital solutions to support growth in the life sciences sector.
